Dr. Laszlo Radvanyi is the President & Scientific Director of the Ontario Institute for Cancer Research (OICR), bringing over 30 years of oncology research background in academia and leadership experience in international pharma and biotech. He is also a Professor in the Immunology Department at the University of Toronto where he performs research on the expression and role of “non-coding regions” including retroelements/retrotransposons, human endogenous retroviruses, and other repeat sequences in anti-tumour immunity and in driving early tumour initiation and progression. Laszlo joined OICR from EMD Serono (Merck KGaA), where he was Senior Vice President Global Head of the Immuno-Oncology Translational Innovation Platform and Senior Scientific Advisor for Immunology and Immunotherapy. Prior to this, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center in Houston for 10 years where he ran an integrated clinical and basic cancer immunotherapy research program focusing on adoptive cell therapy. He was instrumental in launching a pioneering company commercializing cell therapies for melanoma and other cancers, Iovance Therapeutics. Laszlo is a sought-after expert in cancer biology and immunotherapy and a thought leader in the field of oncology research strategy.